CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 23, 2013--
Agios Pharmaceuticals, Inc. today announced the pricing of its initial
public offering of 5,888,888 shares of its common stock at a public
offering price of $18.00 per share, before underwriting discounts. All
of the shares in the offering are being sold by Agios. In addition,
Agios has granted the underwriters a 30-day option to purchase up to
883,333 additional shares of common stock from Agios at the public
offering price, less the underwriting discount. Agios’ common stock has
been approved for listing on the NASDAQ Global Select Market and is
expected to begin trading under the ticker symbol "AGIO" on July 24,
The offering is expected to close on July 29, 2013, subject to customary
J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running
managers for the offering. Cowen and Company and Leerink Swan are acting
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on July 23, 2013.
The offering is being made only by means of a prospectus, copies of
which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 866-803-9204; or Goldman, Sachs, & Co. Attn: Prospectus
Department, 200 West Street, New York, NY 10282, telephone:
866-471-2526, facsimile: 212-902-9316, e-mail: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company passionately
committed to applying its scientific leadership in the field of cellular
metabolism to transform the lives of patients with cancer and inborn
errors of metabolism, or IEMs, which are a subset of orphan genetic
Source: Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.